{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:17:00Z","timestamp":1787314620186,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"DOI":"10.1093\/ehjcvp\/pvx002","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T07:13:54Z","timestamp":1489216434000},"page":"157-162","source":"Crossref","is-referenced-by-count":19,"title":["Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint"],"prefix":"10.1093","volume":"3","author":[{"given":"Jennifer CV","family":"Gwyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,13]]},"reference":[{"key":"key\n\t\t\t\t20171103070509_pvx002-B1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"37","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B4","doi-asserted-by":"crossref","first-page":"e004310.","DOI":"10.1161\/JAHA.116.004310","article-title":"Use of chronic oral anticoagulation and associated outcomes among patients undergoing percutaneous coronary intervention","volume":"5","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1365-2141.2000.02208.x","article-title":"The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity","volume":"110","year":"2000","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B7","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B8","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","year":"2015","journal-title":"Lancet Elsevier"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B10","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO)","volume":"37","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B11","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"ACTIVE Writing Group of the ACTIVE Investigators","year":"2006","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B12","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B14","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","article-title":"New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2015.06.027","article-title":"Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 trial","volume":"66","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"WOEST Study Investigators","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B18","first-page":"260","article-title":"\u2018Triple therapy\u2019 rather than \u2018triple threat\u2019: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment","volume":"139","year":"2011","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B20","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B21","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","article-title":"Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study","volume":"8","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B22","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin k antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ahj.2016.07.015","article-title":"Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy","volume":"180","year":"2016","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2014.10.016","article-title":"Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome","volume":"135","year":"2015","journal-title":"Thromb Res"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B26","first-page":"32","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-386930-2.00006-9","article-title":"Genetics of response to antiplatelet therapy","volume":"124","year":"2014","journal-title":"Prog Mol Biol Transl Sci"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B28","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(14)61994-2","article-title":"Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B29","first-page":"24","article-title":"Optimal management of antiplatelet therapy and proton pump inhibition following percutaneous coronary intervention","volume":"14","year":"2011","journal-title":"Curr Treat Options Cardio Med"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B30","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE trial","volume":"65","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171103070509_pvx002-B31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12265-013-9524-6","article-title":"Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes","volume":"7","year":"2014","journal-title":"J Cardiovasc Transl Res"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/3\/3\/157\/21527604\/pvx002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T11:26:36Z","timestamp":1509708396000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article\/3\/3\/157\/3067525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,13]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,13]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvx002","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,3,13]]}}}